Cart 0 Product Products (empty)
No products
To be determined Shipping
0,00 € Total
Prices are tax excluded
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products (tax excl.)
Total shipping (tax excl.) To be determined
Total (tax excl.)
Data sheet of TFF1 monoclonal antibody (M02), clone 3H5
| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Mouse |
| Applications | S-ELISA,ELISA,WB-Re |
More info about TFF1 monoclonal antibody (M02), clone 3H5
| Brand: | Abnova |
| Reference: | H00007031-M02 |
| Product name: | TFF1 monoclonal antibody (M02), clone 3H5 |
| Product description: | Mouse monoclonal antibody raised against a full length recombinant TFF1. |
| Clone: | 3H5 |
| Isotype: | IgG1 Kappa |
| Gene id: | 7031 |
| Gene name: | TFF1 |
| Gene alias: | BCEI|D21S21|HP1.A|HPS2|pNR-2|pS2 |
| Gene description: | trefoil factor 1 |
| Genbank accession: | BC032811 |
| Immunogen: | TFF1 (AAH32811.1, 1 a.a. ~ 84 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Immunogen sequence/protein sequence: | MATMENKVICALVLVSMLALGTLAEAQTETCTVAPRERQNCGFPGVTPSQCANKGCCFDDTVRGVPWCFYPNTIDVPPEEECEF |
| Protein accession: | AAH32811.1 |
| Storage buffer: | In 1x PBS, pH 7.4 |
| Storage instruction: | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Recombinant Protein. |
| Quality control testing picture: |  |
| Quality control testing picture note: | Western Blot detection against Immunogen (34.98 KDa) . |
| Product type: | Primary antibodies |
| Host species: | Mouse |
| Antigen species / target species: | Human |
| Reactivity: | Human |
| Application image: |  |
| Application image note: | Detection limit for recombinant GST tagged TFF1 is approximately 0.3ng/ml as a capture antibody. |
| Applications: | S-ELISA,ELISA,WB-Re |
| Shipping condition: | Dry Ice |
| Publications: | CRK7 modifies the MAPK pathway and influences the response to endocrine therapy.Iorns E, Martens-de Kemp SR, Lord CJ, Ashworth A. Carcinogenesis. 2009 Oct;30(10):1696-701. Epub 2009 Aug 3. |